FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022346609> ?p ?o ?g. }

• W3022346609 endingPage "221" @default.
• W3022346609 startingPage "205" @default.
• W3022346609 abstract "Atopic dermatitis is the most common inflammatory skin disease and up to 20% of cases can be classified as moderate to severe. Our understanding of the pathogenesis of this disease has improved in recent years. The process is primarily driven by the Th2 pathway, but with significant contributions from the Th22 pathway, the Th1 and Th17 axes, epidermal barrier dysfunction, pruritus, and JAK/STAT signaling. Advances in our understanding of the pathogenesis of atopic dermatitis have led to the development of new systemic treatments. Of particular note are biologic agents targeting IL-4 and IL-13 (e. g., dupilumab, tralokinumab, and lebrikizumab) and small molecules, such as JAK inhibitors (e. g., baricitinib, upadacitinib, and abrocitinib). Novel topical treatments include phosphodiesterase 4 and JAK/STAT inhibitors. In this article, we review the main advances in the treatment of atopic dermatitis. Characterization of clinical and molecular phenotypes with a key pathogenic role is essential for driving these advances. La dermatitis atópica (DA) es la dermatosis inflamatoria más frecuente y hasta un 20% de los casos pueden clasificarse como moderados a graves. En los últimos años se ha producido un avance en el conocimiento de la patogenia, centrada en la vía Th2, pero con una participación marcada de la vía Th22 y de los ejes Th1 y Th17, de la disfunción de barrera epidérmica, el prurito,y la señalización JAK/STAT. Este progreso ha condicionado el desarrollo de nuevas terapias sistémicas, entre las que destacan fármacos biológicos dirigidos frente a la IL-4/13, como dupilumab, tralokinumab y lebrikizumab, pero también moléculas pequeñas, como los inhibidores de JAK, entre los que se incluyen baricitinib, upadicitinib y abrocitinib. Entre las innovaciones en los tratamientos tópicos se incluyen los inhibidores de la PDE4 y de JAK/STAT. Este artículo repasa los principales avances terapéuticos en DA, para los que son esenciales la caracterización de los subtipos clínicos y moleculares clave en su patogénesis." @default.
• W3022346609 created "2020-05-13" @default.
• W3022346609 creator A5049210469 @default.
• W3022346609 creator A5054745950 @default.
• W3022346609 date "2020-04-01" @default.
• W3022346609 modified "2023-10-16" @default.
• W3022346609 title "Innovation in Atopic Dermatitis: From Pathogenesis to Treatment" @default.
• W3022346609 cites W1965217362 @default.
• W3022346609 cites W1974644375 @default.
• W3022346609 cites W1982385791 @default.
• W3022346609 cites W1992025888 @default.
• W3022346609 cites W2003774999 @default.
• W3022346609 cites W2006363519 @default.
• W3022346609 cites W2026140150 @default.
• W3022346609 cites W2068736424 @default.
• W3022346609 cites W2116889630 @default.
• W3022346609 cites W2156992552 @default.
• W3022346609 cites W2467414750 @default.
• W3022346609 cites W2471976905 @default.
• W3022346609 cites W2524051065 @default.
• W3022346609 cites W2568590455 @default.
• W3022346609 cites W2590548546 @default.
• W3022346609 cites W2593200577 @default.
• W3022346609 cites W2598094671 @default.
• W3022346609 cites W2603227160 @default.
• W3022346609 cites W2604389567 @default.
• W3022346609 cites W2606268778 @default.
• W3022346609 cites W2610814011 @default.
• W3022346609 cites W2611397836 @default.
• W3022346609 cites W2613379575 @default.
• W3022346609 cites W2620852772 @default.
• W3022346609 cites W2623658276 @default.
• W3022346609 cites W2728647913 @default.
• W3022346609 cites W2758867833 @default.
• W3022346609 cites W2769784573 @default.
• W3022346609 cites W2771797619 @default.
• W3022346609 cites W2772222829 @default.
• W3022346609 cites W2783616522 @default.
• W3022346609 cites W2783829013 @default.
• W3022346609 cites W2787696154 @default.
• W3022346609 cites W2789092379 @default.
• W3022346609 cites W2790635214 @default.
• W3022346609 cites W2792195584 @default.
• W3022346609 cites W2801208468 @default.
• W3022346609 cites W2802146778 @default.
• W3022346609 cites W2807789068 @default.
• W3022346609 cites W2811091772 @default.
• W3022346609 cites W2887882336 @default.
• W3022346609 cites W2900407403 @default.
• W3022346609 cites W2904559265 @default.
• W3022346609 cites W2904772462 @default.
• W3022346609 cites W2907370710 @default.
• W3022346609 cites W2913106255 @default.
• W3022346609 cites W2914461495 @default.
• W3022346609 cites W2920713085 @default.
• W3022346609 cites W2922786333 @default.
• W3022346609 cites W2932169608 @default.
• W3022346609 cites W2947627101 @default.
• W3022346609 cites W2948249774 @default.
• W3022346609 doi "https://doi.org/10.1016/j.adengl.2020.03.001" @default.
• W3022346609 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31964499" @default.
• W3022346609 hasPublicationYear "2020" @default.
• W3022346609 type Work @default.
• W3022346609 sameAs 3022346609 @default.
• W3022346609 citedByCount "13" @default.
• W3022346609 countsByYear W30223466092021 @default.
• W3022346609 countsByYear W30223466092022 @default.
• W3022346609 countsByYear W30223466092023 @default.
• W3022346609 crossrefType "journal-article" @default.
• W3022346609 hasAuthorship W3022346609A5049210469 @default.
• W3022346609 hasAuthorship W3022346609A5054745950 @default.
• W3022346609 hasBestOaLocation W30223466091 @default.
• W3022346609 hasConcept C16005928 @default.
• W3022346609 hasConcept C203014093 @default.
• W3022346609 hasConcept C2778329239 @default.
• W3022346609 hasConcept C2779824493 @default.
• W3022346609 hasConcept C2780942790 @default.
• W3022346609 hasConcept C71924100 @default.
• W3022346609 hasConceptScore W3022346609C16005928 @default.
• W3022346609 hasConceptScore W3022346609C203014093 @default.
• W3022346609 hasConceptScore W3022346609C2778329239 @default.
• W3022346609 hasConceptScore W3022346609C2779824493 @default.
• W3022346609 hasConceptScore W3022346609C2780942790 @default.
• W3022346609 hasConceptScore W3022346609C71924100 @default.
• W3022346609 hasIssue "3" @default.
• W3022346609 hasLocation W30223466091 @default.
• W3022346609 hasOpenAccess W3022346609 @default.
• W3022346609 hasPrimaryLocation W30223466091 @default.
• W3022346609 hasRelatedWork W2734929597 @default.
• W3022346609 hasRelatedWork W2990762534 @default.
• W3022346609 hasRelatedWork W3017260765 @default.
• W3022346609 hasRelatedWork W3024829390 @default.
• W3022346609 hasRelatedWork W3031700347 @default.
• W3022346609 hasRelatedWork W3041310696 @default.
• W3022346609 hasRelatedWork W3204661765 @default.
• W3022346609 hasRelatedWork W4205257446 @default.
• W3022346609 hasRelatedWork W4221092522 @default.
• W3022346609 hasRelatedWork W4297918273 @default.

• next